ArticleScientific reports2016
Novel MRI Contrast Agent from Magnetotactic Bacteria Enables In Vivo Tracking of iPSC-derived Cardiomyocytes.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Zinc-Based Nanoparticles, but Not Silicon-Based Nanoparticles, Accumulate in Mitochondria and Promote Cell Death in Liver Cancer Cells.International journal of nanomedicine · 2024Article
- Use of Magnetotactic Bacteria as an MRI Contrast Agent for In Vivo Tracking of Adoptively Transferred Immune Cells.Molecular imaging and biology · 2023Article
- Incorporation of Tb and Gd improves the diagnostic functionality of magnetotactic bacteria.Materials today. Bio · 2023Article
- Cellular direct conversion by cell penetrable OCT4-30Kc19 protein and BMP4 growth factor.Biomaterials research · 2022Article
- Magnetic resonance imaging of human neural stem cells in rodent and primate brain.Stem cells translational medicine · 2021Article
- Microbial Nano-Factories: Synthesis and Biomedical Applications.Frontiers in chemistry · 2021Review
- Nanoscale Technologies for Prevention and Treatment of Heart Failure: Challenges and Opportunities.Chemical reviews · 2019Review
- A comprehensive, multiscale framework for evaluation of arrhythmias arising from cell therapy in the whole post-myocardial infarcted heart.Scientific reports · 2019Article
- Safety and Optimization of Metabolic Labeling of Endothelial Progenitor Cells for Tracking.Scientific reports · 2018Article
- Cell Labeling with Magneto-Endosymbionts and the Dissection of the Subcellular Location, Fate, and Host Cell Interactions.Molecular imaging and biology · 2018Article
- Characterization of Magneto-Endosymbionts as MRI Cell Labeling and Tracking Agents.Molecular imaging and biology · 2018Article
- Ferumoxytol-based Dual-modality Imaging Probe for Detection of Stem Cell Transplant Rejection.Nanotheranostics · 2018Article
- Multiscale technologies for treatment of ischemic cardiomyopathy.Nature nanotechnology · 2017Review
- Cellular uptake of nanoparticles: journey inside the cell.Chemical Society reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Therapeutic delivery of human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (iCMs) represents a novel clinical approach to regenerate the injured myocardium. However, methods for robust and accurate in vivo monitoring of the iCMs are still lacking. Although superparamagnetic iron oxide nanoparticles (SPIOs) are recognized as a promising tool for in vivo tracking of stem cells using magnetic resonance imaging (MRI), their signal persists in the heart even weeks after the disappearance of the injected cells. This limitation highlights the inability of SPIOs to distinguish stem cell viability. In order to overcome this shortcoming, we demonstrate the use of a living contrast agent, magneto-endosymbionts (MEs) derived from magnetotactic bacteria for the labeling of iCMs. The ME-labeled iCMs were injected into the infarcted area of murine heart and probed by MRI and bioluminescence imaging (BLI). Our findings demonstrate that the MEs are robust and effective biological contrast agents to track iCMs in an in vivo murine model. We show that the MEs clear within one week of cell death whereas the SPIOs remain over 2 weeks after cell death. These findings will accelerate the clinical translation of in vivo MRI monitoring of transplanted stem cell at high spatial resolution and sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.